DELFI's Boardroom Power Play Signals Push for Lung Cancer Test

PALO ALTO, CA – April 27, 2026 – In a move that signals a major strategic pivot toward commercialization and financial markets, DELFI Diagnostics announced today it has appointed veteran biotech CFO and investment banker Charles "Charlie" Newton to its Board of Directors. The appointment comes at a critical time for the company as it prepares for a pivotal data readout and subsequent FDA submission for its flagship AI-powered blood test for early lung cancer detection, FirstLook™ Lung.

The addition of Newton, renowned for his financial acumen and extensive deal-making experience, is being widely interpreted as a clear signal of DELFI's ambitions. The company, which has developed a novel approach to cancer detection using "fragmentomics," is positioning itself to tackle one of oncology's most significant challenges and is now arming its boardroom with the expertise needed to navigate the path from clinical validation to market dominance.

A Strategic Move on the Cusp of Commercialization

DELFI's leadership framed the appointment as a deliberate step to fortify the company's strategic capabilities as it enters a new phase of growth. "Charlie's deep financial expertise combined with his experience with emerging companies gives him a unique and valuable perspective," said Liz Homans, Chair of the DELFI Diagnostics Board of Directors. "We are thrilled he has chosen to join us in our mission to deliver a paradigm-changing screening test for lung cancer."

Newton's resume underscores his value at this juncture. He most recently served as Chief Financial Officer of Lyell Immunopharma, where he masterminded one of the largest biotech IPOs in NASDAQ history, raising approximately $425 million in 2021. Before his tenure at Lyell, Newton spent over 25 years in healthcare investment banking at top-tier firms including Bank of America Merrill Lynch, Credit Suisse, and Morgan Stanley. During his banking career, he advised on a staggering $200 billion in mergers and acquisitions and helped clients raise nearly $60 billion in capital.

This background is precisely what a company like DELFI needs as it stands on the precipice of major clinical and regulatory milestones. "Charlie's addition to our Board reflects where DELFI is today — we are on the cusp of unblinding pivotal clinical data, and we have an FDA submission on the horizon," said Susan Tousi, Chief Executive Officer of DELFI Diagnostics. Tousi also hinted at Newton's potential role in future growth strategies, stating, "I look forward to his counsel as we evaluate transformative partnerships that could accelerate our growth and clinical impact."

For his part, Newton acknowledged the unique opportunity presented by DELFI. "DELFI is tackling one of the most important unmet needs in oncology, and the combination of a differentiated fragmentomics platform, an integrated AI approach, a clear path to FDA approval and broad reimbursement makes this an exciting time to join the Board," he said in a statement.

The Promise of Fragmentomics in a Vast Unmet Need

The problem DELFI aims to solve is both enormous and tragic. Lung cancer remains the leading cause of cancer-related death in the United States, largely because it is often detected at late stages when treatment options are limited and survival rates are grim. The current standard for screening high-risk individuals is a low-dose computed tomography (LDCT) scan. While proven to save lives, its adoption is critically low, with estimates suggesting that fewer than 18%—and in some regions, less than 1%—of eligible individuals get screened annually due to barriers like cost, access, and patient apprehension.

This is the gap FirstLook Lung is designed to fill. The test uses a simple blood draw, which can be integrated into routine clinical care, to analyze patterns of circulating cell-free DNA (cfDNA) fragments in the bloodstream. The company's proprietary AI platform then deciphers these "fragmentomics" patterns to detect signals associated with lung cancer.

Recent data from the company's pivotal L101 study, published in the prestigious journal Cancer Discovery, showcased the test's potential. The study demonstrated 80% sensitivity across all stages of the disease and an impressive negative predictive value (NPV) of 99.8%. This high NPV is particularly crucial for a screening tool, as it means a "not elevated" result provides strong assurance that a person has a very low probability of having lung cancer, potentially helping to triage patients and direct those at highest risk toward confirmatory LDCT scans. The test has already received a Breakthrough Device designation from the FDA, underscoring its potential.

Navigating a Crowded and Competitive Field

DELFI is not alone in the quest for a blood-based cancer screening test. The "liquid biopsy" space is a hotbed of innovation and intense competition, with several well-funded players vying for market leadership. Companies like Guardant Health, with its ongoing SHIELD LUNG study, and Grail, with its multi-cancer Galleri test, are also making significant strides in early detection.

However, the market is nuanced. Many existing liquid biopsy tests, such as Guardant360 and FoundationOne Liquid CDx, are FDA-approved as companion diagnostics to guide treatment decisions for patients already diagnosed with advanced cancer. DELFI's FirstLook Lung is positioned squarely in the early screening space for asymptomatic, high-risk individuals—a different and potentially much larger market, but one with a higher bar for clinical validation and regulatory approval.

A significant hurdle for all companies in this space is reimbursement. Currently, the Centers for Medicare & Medicaid Services (CMS) does not have a clear pathway to cover blood-based screening tests for lung cancer. Gaining widespread reimbursement will require not only FDA approval but also robust data demonstrating clinical utility and cost-effectiveness, a long and expensive process that will test the financial endurance of any company.

Building a Financial Fortress for a Biotech Breakthrough

This is precisely why the appointment of Charles Newton is so significant. Navigating the complex landscape of FDA approvals, competitive pressures, and reimbursement negotiations requires more than just groundbreaking science; it requires a formidable financial strategy and the capital to execute it. DELFI has already built a strong foundation, having raised over $330 million in financing from a syndicate of top-tier investors including OrbiMed, DFJ Growth, and Eli Lilly and Company.

Newton's arrival signals that the company is now preparing for its next major financial chapter. His expertise in taking companies public, securing massive capital infusions, and architecting strategic M&A deals provides DELFI with a powerful new asset. His presence on the board sends a clear message to the market: DELFI is not just a science-driven startup, but a serious commercial enterprise preparing to compete at the highest level. By combining its innovative fragmentomics platform with elite financial leadership, DELFI is betting it has the right formula to transform the fight against lung cancer.